TY - JOUR
T1 - Supraventricular arrhythmia in pregnancy
AU - Ramlakhan, Karishma P.
AU - Kauling, Robert M.
AU - Schenkelaars, Nicole
AU - Segers, Dolf
AU - Yap, Sing Chien
AU - Post, Martijn C.
AU - Cornette, Jérôme
AU - Roos-Hesselink, Jolien W.
N1 - Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.
PY - 2022/10/13
Y1 - 2022/10/13
N2 - The physiological changes during pregnancy predispose a woman for the development of new-onset or recurrent arrhythmia. Supraventricular arrhythmia is the most common form of arrhythmia during pregnancy and, although often benign in nature, can be concerning. We describe three complex cases of supraventricular arrhythmia during pregnancy and review the currently available literature on the subject. In pregnancies complicated by arrhythmia, a plan for follow-up and both maternal and fetal monitoring during pregnancy, delivery and post partum should be made in a multidisciplinary team. Diagnostic modalities should be used as in non-pregnant women if there is an indication. All antiarrhythmic drugs cross the placenta, but when necessary, medical treatment should be used with consideration to the fetus and the mother's altered pharmacodynamics and kinetics. Electrical cardioversion is safe during pregnancy, and electrophysiological study and catheter ablation can be performed in selected patients, preferably with zero-fluoroscopy technique. Sometimes, delivering the fetus (if viable) is the best therapeutic option. In this review, we provide a framework for the workup and clinical management of supraventricular arrhythmias in pregnant women, including cardiac, obstetric and neonatal perspectives.
AB - The physiological changes during pregnancy predispose a woman for the development of new-onset or recurrent arrhythmia. Supraventricular arrhythmia is the most common form of arrhythmia during pregnancy and, although often benign in nature, can be concerning. We describe three complex cases of supraventricular arrhythmia during pregnancy and review the currently available literature on the subject. In pregnancies complicated by arrhythmia, a plan for follow-up and both maternal and fetal monitoring during pregnancy, delivery and post partum should be made in a multidisciplinary team. Diagnostic modalities should be used as in non-pregnant women if there is an indication. All antiarrhythmic drugs cross the placenta, but when necessary, medical treatment should be used with consideration to the fetus and the mother's altered pharmacodynamics and kinetics. Electrical cardioversion is safe during pregnancy, and electrophysiological study and catheter ablation can be performed in selected patients, preferably with zero-fluoroscopy technique. Sometimes, delivering the fetus (if viable) is the best therapeutic option. In this review, we provide a framework for the workup and clinical management of supraventricular arrhythmias in pregnant women, including cardiac, obstetric and neonatal perspectives.
KW - arrhythmias
KW - atrial fibrillation
KW - atrial flutter
KW - cardiac
KW - pregnancy
KW - supraventricular
KW - tachycardia
UR - http://www.scopus.com/inward/record.url?scp=85139880573&partnerID=8YFLogxK
U2 - 10.1136/heartjnl-2021-320451
DO - 10.1136/heartjnl-2021-320451
M3 - Review article
C2 - 35086889
AN - SCOPUS:85139880573
SN - 1355-6037
VL - 108
SP - 1674
EP - 1681
JO - Heart (British Cardiac Society)
JF - Heart (British Cardiac Society)
IS - 21
M1 - heartjnl-2021-320451
ER -